STAT gathered reactions from leaders across biotech and pharma about what the new Trump era could mean for them.

Amid swirling speculation, Bausch + Lomb ($BLCO), a global leader in the contact lens supply industry, is reportedly ...

The company operates through five main business segments — Bausch + Lomb, Salix Pharmaceuticals, International Rx, Solta ...

Bausch + Lomb Corp. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) yesterday and set a ...

The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products ...

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its third-quarter 2024 finan ...

Bausch + Lomb (NYSE:BLCO – Get Free Report) is scheduled to be posting its quarterly earnings results before the market opens ...

Bausch Health shares rose Thursday morning after the company raised its full year outlook following a better-than-expected third-quarter performance. Shares traded over 11% higher in Toronto at 12.68 ...

In a report released yesterday, Douglas Miehm from RBC Capital assigned a Buy rating to Aurinia Pharmaceuticals (AUPH – Research Report), ...

Bausch + Lomb (NYSE:BLCO – Get Free Report)‘s stock had its “hold” rating reaffirmed by research analysts at Needham & ...